Electronic Church

Weight loss drugs-Will they decrease the risk of ACS?

There are many people who are obese and according to the research done, these people are of the greatest proportion of having the CVD or ACS attack with in 3 years time. On the other hand, many pharmaceutical companies are making many new drugs to attract many of these people by giving them the drugs which will save them by controlling their fat in the body. Along with this, there are many other options which are also available for making the good

impression on the body. Not only this, people are also taking these medicines. For some, the outcomes of these medications is quite good, while on the other hand, the outcomes is not that much satisfactory and these are making the life of many people quite difficult to be spent.
According to the 4 phase III trials, the using of the drugs namely Naltrexone and Bupropion has shown that the risk of the ACS to be happening in these patients are reduced many folds for nearly 10 years. According to the Texas Health Science Center which is located in San Antonio, there is one combination proposed and being used for the treatment of the patients. Hence, when the trials are done, the CVD death rates are reduced by 0.17%, while on the other patients; it has been reduced by 0.05% for the people who are using it.

There are several randomized trials done on the patients, and with the great security, there is the great proportion of the people who are having the good numbers. Hence, not only the weight reduction was satisfactory, but the other factors are also needed to be controlled for this too. Most of these factors are required to be used for the treatment of the obesity and it included the diet. Not only will it control the weight, but the risk of having the attack of ACS is also reduced. Along with this, another drug is also put forward by FDA namely Orexigen, and when the trials are done on it, there are great hopes that it will generate the great outcomes for it.

The trial on all these 3 drugs went quite great and with the exception of 1.5%, the results of the randomized trials on the obese patients were great. Hence, according to the FDA, the use of these drugs will be quite feasible and will yield the great outcomes.